Celgene Corp. to pay $280M to settle cancer drug fraud suit

LOS ANGELES (AP) -- A New Jersey pharmaceutical company has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud by promoting a drug for leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday....

Read the whole article on AP Health

More from AP Health